Aug 24 (Reuters) - Catalent Inc said on Monday it will manufacture active ingredient for AstraZeneca Plc and the University of Oxford’s COVID-19 vaccine candidate.
It will be made at Catalent’s commercial gene therapy manufacturing facility located in Harmans, Maryland, the company said. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.